Cargando…

Ruling out lupus anticoagulants with mixing test–specific cutoff assessment and the index of circulating anticoagulant

BACKGROUND: Lupus anticoagulant (LA) is classified in the antibody family that is recognized in antiphospholipid syndrome. Mixing tests are recommended for LA detection, and either a mixing test–specific cutoff (MTC) or index of circulating anticoagulant (ICA) is used for the interpretation. Althoug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumano, Osamu, Moore, Gary W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles: Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781930/ https://www.ncbi.nlm.nih.gov/pubmed/31624789 http://dx.doi.org/10.1002/rth2.12245

Ejemplares similares

Lupus anticoagulant mixing tests for multiple reagents are more sensitive if interpreted with a mixing test‐specific cut‐off than index of circulating anticoagulant
por: Kumano, Osamu, et al.
Publicado: (2017)

DOAC‐Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples
por: Baker, Steven Andrew, et al.
Publicado: (2021)

Lupus anticoagulant test persistence over time and its associations with future thrombotic events
por: Colling, Meaghan E., et al.
Publicado: (2022)

Anti‐β2‐glycoprotein I and anti‐prothrombin antibodies cause lupus anticoagulant through different mechanisms of action
por: Noordermeer, Tessa, et al.
Publicado: (2021)

Outcomes in patients undergoing periprocedural interruption of warfarin or direct oral anticoagulants
por: Lee, Jeffrey, et al.
Publicado: (2022)

Barriers to integrating direct oral anticoagulants into anticoagulation clinic care: A mixed‐methods study
por: Barnes, Geoffrey D., et al.
Publicado: (2018)

Defective fibrin deposition and thrombus stability in Bambi (−/−) mice are mediated by elevated anticoagulant function
por: Crawley, James T. B., et al.
Publicado: (2019)

Sex‐specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants—A substudy of the EINSTEIN‐PE study
por: Wiegers, Hanke M. G., et al.
Publicado: (2021)

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)

Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a)
por: Pasternack, Ralf, et al.
Publicado: (2019)

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD‐AF registry
por: Seelig, Jaap, et al.
Publicado: (2020)

Extended anticoagulation treatment for cancer‐associated thrombosis—Rates of recurrence and bleeding beyond 6 months: A systematic review
por: Moik, Florian, et al.
Publicado: (2021)

D‐dimer to rule out venous thromboembolism during pregnancy: A systematic review and meta‐analysis
por: Bellesini, Marta, et al.
Publicado: (2021)

The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing: Can activated carbon eliminate false‐positive results?
por: De Kesel, Pieter M.M., et al.
Publicado: (2019)

Cost-effectiveness analysis of alternative anticoagulation in suspected heparin-induced thrombocytopenia
por: Tuleja, Aleksandra, et al.
Publicado: (2022)

Out‐of‐range INR results lead to increased health‐care utilization in four large anticoagulation clinics
por: Barnes, Geoffrey D, et al.
Publicado: (2018)

The Impact of Degree of Anticoagulation on Thrombotic and Other Complications in Hospitalized COVID-19 Patients
por: Zheng, Rena, et al.
Publicado: (2021)

Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
por: Carney, Brian J., et al.
Publicado: (2021)

Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis
por: Candeloro, Matteo, et al.
Publicado: (2022)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

Safety of using the combination of the Wells rule and D‐dimer test for excluding acute recurrent ipsilateral deep vein thrombosis
por: van Dam, Lisette F., et al.
Publicado: (2020)

Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants
por: Favaloro, Emmanuel J., et al.
Publicado: (2022)

Impact of Treatment and Anticoagulation on Thrombosis in COVID-19 Patients
por: Warrior, Surbhi, et al.
Publicado: (2020)

Current Controversies in Lupus Anticoagulant Detection
por: Moore, Gary W.
Publicado: (2016)

Anticoagulation practice patterns in COVID‐19: A global survey
por: Rosovsky, Rachel P., et al.
Publicado: (2020)

Blocking human protein C anticoagulant activity improves clotting defects of hemophilia mice expressing human protein C
por: Jiang, Miao, et al.
Publicado: (2022)

Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism
por: Moustafa, Farès, et al.
Publicado: (2017)

Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism
por: Berger, Jeffrey S., et al.
Publicado: (2017)

Quality of anticoagulant therapy and the incidence of in‐stent thrombosis after venous stenting
por: Notten, Pascale, et al.
Publicado: (2020)

Anticoagulation in splanchnic and cerebral vein thrombosis: An international vignette‐based survey
por: Riva, Nicoletta, et al.
Publicado: (2020)

Dental extractions on direct oral anticoagulants vs. warfarin: The DENTST study
por: Brennan, Yvonne, et al.
Publicado: (2020)

Impaired factor V–related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations
por: Shimonishi, Naruto, et al.
Publicado: (2023)

Management of anticoagulation for cancer‐associated thrombosis in patients with thrombocytopenia: A systematic review
por: Samuelson Bannow, Bethany R., et al.
Publicado: (2018)

Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system
por: Pfrepper, Christian, et al.
Publicado: (2020)

Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants
por: Metze, Michael, et al.
Publicado: (2020)

Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis
por: Martin, Karlyn A., et al.
Publicado: (2020)

Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study
por: Zielinski, Gilda Denise, et al.
Publicado: (2019)

Updates on Anticoagulation and Laboratory Tools for Therapy Monitoring of Heparin, Vitamin K Antagonists and Direct Oral Anticoagulants
por: Kumano, Osamu, et al.
Publicado: (2021)

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib
por: Jones, Jeffrey A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_opb8qi0fokncuc3e9el4dded83